Seeking Alpha

Salix (SLXP -9.5%) shares slump on heavy trading after the FDA raises questions about the...

Salix (SLXP -9.5%) shares slump on heavy trading after the FDA raises questions about the drugmaker's non-constipation irritable bowel syndrome treatment Xifaxan ahead of a Nov. 16 committee meeting. Some experts believe the unexpected questions could complicate approval, although others expect the drug ultimately will be approved.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|